Abstract
Functional recovery following acute CNS injury in humans, such as spinal cord injury and stroke, is exceptionally limited, leaving the affected individual with life-long neurological deficits such as loss of limb movement and sensation leading to a compromised quality of life. As yet, there is no effective treatment on the market for such injuries. This lack of functional recovery can at least in part be attributed to the restriction of axonal regeneration and neuroplasticity by several CNS myelin proteins that have been shown to be potent inhibitors of neurite outgrowth in vitro, namely myelin-associated glycoprotein (MAG), Nogo-A and oligodendrocyte myelin glycoprotein (OMgp). Nogo-A contains multiple neurite outgrowth inhibitory domains exposed on the surface of myelinating oligodendrocytes located within its amino-terminal region (amino-Nogo-A) and C-terminal region (Nogo-66). Although structurally dissimilar; Nogo-66, MAG and OMgp exert their inhibitory effects by binding the GPI-linked neuronal Nogo-66 receptor (NgR) that transduces the inhibitory signal to the cell interior via transmembrane co-receptors LINGO-1 and p75NTR or TROY. Although the receptor(s) for amino- Nogo-A are unknown, amino-Nogo-A and NgR ligands mutually activate the small GTPase RhoA. Consistent with their neurite outgrowth inhibitory function, approaches counter-acting Nogo-A using function-blocking antibodies, NgR using peptide antagonists and receptor bodies or RhoA using deactivating enzymes have been shown to significantly enhance axonal regeneration and neuroplasticity leading to improved functional recovery in animal models of acute CNS injury. These in vivo findings thus provide a sound basis for the development of an effective treatment for acute CNS injuries in humans.
Keywords: Acute CNS injury, antibodies, axonal regeneration, myelin, neuroplasticity, Nogo-A, Nogo-66 receptor
Current Pharmaceutical Design
Title: Targeting the Nogo-A Signalling Pathway to Promote Recovery Following Acute CNS Injury
Volume: 13 Issue: 24
Author(s): A. R. Walmsley and A. K. Mir
Affiliation:
Keywords: Acute CNS injury, antibodies, axonal regeneration, myelin, neuroplasticity, Nogo-A, Nogo-66 receptor
Abstract: Functional recovery following acute CNS injury in humans, such as spinal cord injury and stroke, is exceptionally limited, leaving the affected individual with life-long neurological deficits such as loss of limb movement and sensation leading to a compromised quality of life. As yet, there is no effective treatment on the market for such injuries. This lack of functional recovery can at least in part be attributed to the restriction of axonal regeneration and neuroplasticity by several CNS myelin proteins that have been shown to be potent inhibitors of neurite outgrowth in vitro, namely myelin-associated glycoprotein (MAG), Nogo-A and oligodendrocyte myelin glycoprotein (OMgp). Nogo-A contains multiple neurite outgrowth inhibitory domains exposed on the surface of myelinating oligodendrocytes located within its amino-terminal region (amino-Nogo-A) and C-terminal region (Nogo-66). Although structurally dissimilar; Nogo-66, MAG and OMgp exert their inhibitory effects by binding the GPI-linked neuronal Nogo-66 receptor (NgR) that transduces the inhibitory signal to the cell interior via transmembrane co-receptors LINGO-1 and p75NTR or TROY. Although the receptor(s) for amino- Nogo-A are unknown, amino-Nogo-A and NgR ligands mutually activate the small GTPase RhoA. Consistent with their neurite outgrowth inhibitory function, approaches counter-acting Nogo-A using function-blocking antibodies, NgR using peptide antagonists and receptor bodies or RhoA using deactivating enzymes have been shown to significantly enhance axonal regeneration and neuroplasticity leading to improved functional recovery in animal models of acute CNS injury. These in vivo findings thus provide a sound basis for the development of an effective treatment for acute CNS injuries in humans.
Export Options
About this article
Cite this article as:
A. R. Walmsley and A. K. Mir , Targeting the Nogo-A Signalling Pathway to Promote Recovery Following Acute CNS Injury, Current Pharmaceutical Design 2007; 13 (24) . https://dx.doi.org/10.2174/138161207781368611
DOI https://dx.doi.org/10.2174/138161207781368611 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MR Spectroscopy in Metabolic Profiling Studies of Stem Cells
Current Medical Imaging Overview of Brain Tumor Stem Cells – Implications for Treatment
Current Signal Transduction Therapy Neuregulin Signaling in Pieces-Evolution of the Gene Family
Current Pharmaceutical Design Human Amnion–Derived Cells as a Reliable Source of Stem Cells
Current Molecular Medicine Optic Neuritis: A Model for the Immuno-pathogenesis of Central Nervous System Inflammatory Demyelinating Diseases
Current Immunology Reviews (Discontinued) The Plastic Phenomenon Underlying the Associative Processes in the Addictive Properties of Diazepam and Other Psychoactive Drugs
Mini-Reviews in Medicinal Chemistry Somatostatin Type 2 Receptor Antibody Enhances Mechanical Hyperalgesia in the Dorsal Root Ganglion Neurons after Sciatic Nerve-pinch Injury: Evidence of Behavioral Studies and Bax Protein Expression
CNS & Neurological Disorders - Drug Targets NEP1-40-overexpressing Neural Stem Cells Enhance Axon Regeneration by Inhibiting Nogo-A/NgR1 Signaling Pathway
Current Neurovascular Research The Role of Pericytes in Blood-Brain Barrier Function and Stroke
Current Pharmaceutical Design Misoprostol Reverse Hippocampal Neuron Cyclooxygenase-2 Downstream Signaling Imbalance in Aluminum-Overload Rats
Current Alzheimer Research Probiotics: An Emerging Therapy
Current Pharmaceutical Design Posttranslational Modifications of Tau - Role in Human Tauopathies and Modeling in Transgenic Animals
Current Drug Targets Nanoparticle Therapy for Allergic and Inflammatory Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Heterocyclic Secretase Inhibitors for the Treatment of Alzheimer’s Disease: An Overview
Central Nervous System Agents in Medicinal Chemistry Modified Polysaccharides as Versatile Materials in Controlled Delivery of Antidegenerative Agents
Current Pharmaceutical Design Recent Updates in Imperative Natural Compounds for Healthy Brain and Nerve Function: A Systematic Review of Implications for Multiple Sclerosis
Current Drug Targets Antioxidant Properties of Crocus Sativus L. and Its Constituents and Relevance to Neurodegenerative Diseases; Focus on Alzheimer’s and Parkinson’s Disease
Current Neuropharmacology The Role of Mitochondria in Brain Aging and the Effects of Melatonin
Current Neuropharmacology Development of Nucleic Acid Drugs for Neurological Disorders
Current Topics in Medicinal Chemistry The Valsalva Maneuver and Alzheimers Disease: Is there a link?
Current Alzheimer Research